MetaCap

IRulya Therapeutics (IRLA) vs Valneva (VALN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Valneva is the larger company by market cap ($490.9 million vs $432.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IRLA+17.16%VALN-27.63%
+22%-4%-30%
Aug 14, 20261 yearNov 20, 2026
IRLA+17.16%VALN-27.63%
+19%-5%-30%
Aug 10, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IRLA versus VALN key metrics
MetricIRLAVALN
Share price$39.88$5.16
Market cap$432.36M$490.86M
1-day change-0.15%-3.82%
YTD return—-41.50%
1-year return—-40.14%
5-year return—-91.34%
Forward P/E—4.34
EPS (TTM)$-162.79$-2.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-83.98M—
52-week high$910.00$12.18
52-week low$15.10$4.75
Distance from 52-week high-95.62%-57.64%
Analyst consensusstrong_buynone
Avg. price target upside+90.90%+137.98%
Average volume63.03K23.10K
Shares outstanding10.84M95.13M
Employees38620
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About IRulya Therapeutics

IRLA stock →

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees

About Valneva

VALN stock →

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees

IRLA vs VALN FAQ

Which is bigger, IRulya Therapeutics or Valneva?

Valneva (VALN) is larger, with a market capitalization of $490.86M compared with $432.36M for IRulya Therapeutics (IRLA).

Are IRulya Therapeutics and Valneva in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons